Eli Lilly stories

Mar 29, 2026

Eli Lilly Expands AI Drug Discovery Partnership with Insilico Medicine in Deal Worth Up to $2.75 Billion

Pharmaceutical giant Eli Lilly has agreed to a global licensing and research collaboration with AI drug developer Insilico Medicine, providing $115 million upfront with potential total value reaching $2.75 billion. The deal expands an existing partnership focused on using artificial intelligence for drug discovery.

Mar 29, 2026·4 sources

Eli Lilly Signs $2.75 Billion AI Drug Development Deal with Insilico Medicine

US pharmaceutical giant Eli Lilly has entered a $2.75 billion partnership with Hong Kong-listed AI drug developer Insilico Medicine, marking one of the largest AI-pharma deals to date.

Mar 29, 2026·1 source

Mar 26, 2026

FDA Approves Rocket Pharmaceuticals Gene Therapy for Rare Immune Disorder

The FDA approved Kresladi, Rocket Pharmaceuticals' gene therapy for a rare immune disorder, despite testing in only nine patients. The approval represents a notable decision as the agency has recently taken tougher stances on rare disease drugs.

Mar 26, 2026·3 sources

Top claims

▪Insilico Medicine's pipeline webpage was recently updated to note that a candidate targeting GLP-1 has been out-licensed to an undisclosed partner.
▪Eli Lilly and Insilico Medicine announced a commercialization deal on Sunday, March 29, 2026.
▪The Insilico Medicine and Eli Lilly deal includes approximately $2.75 billion in biobucks contingent on achieving regulatory and commercial milestones.

Topics

AI tools & products AI startups Business & enterprise AI AI Rare Disease

Related entities

Hong Kong United States Novo Nordisk South Africa

Featured Stories

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

Aug 7, 2026·2 sources